Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Canertinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 9/20 | 1.00 |
| ▸ | ERBB4 known ✓ | Q15303 | 3/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | MAP2K7 | O14733 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | STK17B | O94768 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Canertinib SCHEMBL29368458 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL54837 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL29623482 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL2141065 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL30436576 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL2052123 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL731396 | 0.99 | EGFR (0.97) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL3585133 | 0.93 | EGFR (0.88) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL30415948 | 0.93 | EGFR (0.88) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL13882947 | 0.93 | EGFR (0.86) | EGFRERBB2ERBB4KITSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4291902-A2 | BIOMARKERS FOR CANCER TREATMENT | Foundation Medicine, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4240368-A1 | METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASES | MAX Biopharma, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| WO-2022174234-A2 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | ASTRAZENECA AB (SE) | 2022-06-07 | — | — | US | disclosed |
| WO-2022098907-A1 | METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASES | MAX BioPharma, Inc. (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | EGFR 1273/4885ERBB2 567/4885ERBB4 1871/4885 |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | CDK9, BCL9, CDK19 | EGFR 2049/4885ERBB2 465/4885ERBB4 472/4885 |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | EGFR 1273/4885ERBB2 567/4885ERBB4 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.